TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23817865

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention program (exercise, diet, hot bath)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Exercise and diet intervention
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hot bath intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study: 22092168

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 50
Study: 18825612

Group type: EXPERIMENTAL
Intervention: Diet type I (low fat)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Diet type II (low carbohydrate)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both diets for carriers of T variant
Number of subjects: 131
Study: 16943177

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12905078

Group type: EXPERIMENTAL
Intervention: Iliac crest autograft
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rectangular titanium cages
Number of subjects: 36
Study: 11587994

Group type: EXPERIMENTAL
Intervention: Environmental tobacco smoke (ETS) exposure
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Active smoke inhalation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham inhalation
Number of subjects: 37
Study: 9403257

Group type: EXPERIMENTAL
Intervention: Povidone-iodine rinsing 4 times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sterile water rinsing (Control)
Number of subjects: 40
Study: 7520905

Group type: EXPERIMENTAL
Intervention: Risperidone at doses of 6, 10, and 16 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol at a dose of 20 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3294067

Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 5687606

Group type: EXPERIMENTAL
Intervention: Clinically observed foetal heart rate > 160 beats per minute
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steady foetal heart rate 100-120 beats per minute
Number of subjects: 0
Study: 31234672

Group type: EXPERIMENTAL
Intervention: Outpatient visits for migraine in the physician's office
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Emergency room visits
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Hospitalization for migraine
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Blood tests
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Computerized tomography (CT) scan
Number of subjects: 168
Study: 28134562

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study: 28977202

Group type: EXPERIMENTAL
Intervention: PEEP 15
Number of subjects: 30

Group type: COMPARATOR
Intervention: PEEP 10
Number of subjects: 30

Group type: COMPARATOR
Intervention: PEEP 12
Number of subjects: 30
Study: 23714166

Group type: EXPERIMENTAL
Intervention: Sterimar™
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sinus Rinse™
Number of subjects: 31
Study: 21848706

Group type: EXPERIMENTAL
Intervention: Roflumilast, 500 µg once daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 20141008

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (500 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Emoxypin (150 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 100
Study: 17270317

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (7.2 g/day for 14 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (7.2 g/day for 14 days) in fasting conditions
Number of subjects: 8
Study: 15073101

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 187

Group type: COMPARATOR
Intervention: IFN + 1-beta-D-arabinofuranosylcytosine
Number of subjects: 187
Study: 11231986

Group type: EXPERIMENTAL
Intervention: L-thyroxine [64 nmol.day(‐)(1) (0.05 mg.day(‐)(1))]
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both groups (L-thyroxine and placebo)
Number of subjects: 12
Study: 9022429

Group type: EXPERIMENTAL
Intervention: Routine follow up restricted to the time of mammography
Number of subjects: 211

Group type: COMPARATOR
Intervention: Conventional schedule of clinic visits
Number of subjects: 211
Study: 7930987

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation in patients with overt accessory AV connections (group 1)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation in patients with concealed accessory AV connections (group 2)
Number of subjects: 51
Study: 3369246

Group type: EXPERIMENTAL
Intervention: Patient education program for rheumatoid arthritis (8 hours over 3 months)
Number of subjects: 34
Study: 29544801

Group type: EXPERIMENTAL
Intervention: Optimal-mineral-content diet (group D)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (group S)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No changes in diet or zinc supplementation (group C)
Number of subjects: 98
Study: 26985696

Group type: EXPERIMENTAL
Intervention: HIFU Device 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HIFU Device 2
Number of subjects: 20
Study: 23868932

Group type: EXPERIMENTAL
Intervention: 12-month follow-up interval
Number of subjects: 155

Group type: COMPARATOR
Intervention: 3-month follow-up interval
Number of subjects: 155
Study: 23520976

Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg/mL, 0.5 mL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (isotonic saline, 9 mg/mL, 0.5 mL)
Number of subjects: 28
Study: 20535948

Group type: EXPERIMENTAL
Intervention: Bevacizumab (antiangiogenesis therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Small molecules of VEGF-TKI
Number of subjects: 0
Study: 18177773

Group type: EXPERIMENTAL
Intervention: Polychemotherapy
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 6000
Study: 16504154

Group type: EXPERIMENTAL
Intervention: IFNalfa‐2b 20 MU/m2/d IV 5 days/week x 4 weeks, repeated for three times on weeks 9 to 12, 17 to 20, 25 to 28 (DD/DI arm)
Number of subjects: 169

Group type: COMPARATOR
Intervention: IFNalfa‐2b 20 MU/m2/d IV 5 days/week x 4 weeks followed by 10 MU/m2 SC three times per week x 48 weeks (HDI arm)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: DD/DI arm
Number of subjects: 169
Study: 14621092

Group type: EXPERIMENTAL
Intervention: Nasal breathing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral breathing
Number of subjects: 12
Study: 10732258

Group type: EXPERIMENTAL
Intervention: CASA volunteers
Number of subjects: 200

Group type: COMPARATOR
Intervention: No CASA volunteers (Control)
Number of subjects: 200
Study: 8881615

Group type: EXPERIMENTAL
Intervention: Sprotte spinal needle orientation pointing cephalad (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sprotte spinal needle orientation pointing right lateral (group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sprotte spinal needle orientation pointing left lateral (group C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sprotte spinal needle orientation pointing caudad (group D)
Number of subjects: 100
Study: 8267489

Group type: EXPERIMENTAL
Intervention: Anti-factor Xa monitoring (targeted range, 0.35 to 0.67 U/mL)
Number of subjects: 131

Group type: COMPARATOR
Intervention: APTT monitoring (targeted range, 60 to 85 seconds)
Number of subjects: 131

Group type: COMPARATOR
Intervention: APTT monitoring
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Anti-factor Xa monitoring
Number of subjects: 131
Study: 3114564

Group type: EXPERIMENTAL
Intervention: Histamine (0.06‐2 micrograms in 0.1 ml saline)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Terfenadine (20, 40, 60, and 120 mg, p.o.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29336898

Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cathodal stimulation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 27039756

Group type: EXPERIMENTAL
Intervention: Mouth Exercising Device (MED) in subgroup A1 (n=53)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Mouth Exercising Device (MED) in subgroup A2 (n=46)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Mouth Exercising Device (MED) in subgroup A3 (n=18)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group B1 (n=50)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group B2 (n=48)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group B3 (n=16)
Number of subjects: 231
Study: 24245838

Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Internet (control group)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Disruptiveness
Number of subjects: 285
Study: 23726115

Group type: EXPERIMENTAL
Intervention: voluntary deep-inspiratory breath-hold (v_DIBH)
Number of subjects: 23

Group type: COMPARATOR
Intervention: deep-inspiratory breath-hold with the active breathing coordinator™ (ABC_DIBH)
Number of subjects: 23
Study: 20627451

Group type: EXPERIMENTAL
Intervention: Low intensity behavioral treatment (average 6.5h per week)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Regular intervention (control group)
Number of subjects: 34
Study: 18979977

Group type: EXPERIMENTAL
Intervention: Body image challenge with thin model images and smoking cues
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Body image challenge with thin model images without smoking cues
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control images
Number of subjects: 62
Study: 16409338

Group type: EXPERIMENTAL
Intervention: IMPACT service (Inpatient Management of acute Pain and Advice on Clinical Treatment)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Standard acute pain management (baseline phase)
Number of subjects: 590
Study: 14636098

Group type: EXPERIMENTAL
Intervention: High-intensity intervals (MAX)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continuous submaximal (SUB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 24-hour recovery condition
Number of subjects: 16
Study: 10987602

Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg and 125 mg
Number of subjects: 384

Group type: COMPARATOR
Intervention: Azimilide 50 mg
Number of subjects: 384

Group type: COMPARATOR
Intervention: Azimilide 100 mg
Number of subjects: 384

Group type: COMPARATOR
Intervention: Azimilide 125 mg
Number of subjects: 384
Study: 8621870

Group type: EXPERIMENTAL
Intervention: Sweetened flaked corn cereal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Unsweetened flaked corn cereal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 24
Study: 1597329

Group type: EXPERIMENTAL
Intervention: Home training programme for mothers
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 3085131

Group type: EXPERIMENTAL
Intervention: Mecamylamine (2.5, 5.0, 10, 20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29522439

Group type: EXPERIMENTAL
Intervention: Resveratrol (RV)
Number of subjects: 70
Study: 26701793

Group type: EXPERIMENTAL
Intervention: MFGM (10 g Lacprodan PL-20, twice daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (10 g Miprodan 30, twice daily)
Number of subjects: 58
Study: 25477073

Group type: EXPERIMENTAL
Intervention: Tablet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Smartphone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Computer
Number of subjects: 120
Study: 22709382

Group type: EXPERIMENTAL
Intervention: Experienced group (n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inexperienced group (n=11)
Number of subjects: 22
Study: 20503005

Group type: EXPERIMENTAL
Intervention: Activator
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bite-jumping appliance
Number of subjects: 40
Study: 18377130

Group type: EXPERIMENTAL
Intervention: Cognitive dissonance (CD) intervention
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Media advocacy (MA) intervention
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 188
Study: 15802340

Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention to reduce exposure to allergens and passive smoking (n = 222)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Usual care (control group, n = 221)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention (n = 222)
Number of subjects: 476
Study: 12182742

Group type: EXPERIMENTAL
Intervention: Omeprazole triple therapy
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1497
Study: 10350225

Group type: EXPERIMENTAL
Intervention: Screening questionnaire (adapted from ECRHS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical evaluation (history, physical examination, skin prick tests, serum total IgE, phadiotop measurements)
Number of subjects: 0
Study: 7669310

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with alfentanil (0.5 mcg/kg initial dose, continuous infusion 0.2 to 0.5 mcg/kg/min, self-administered 3 to 5 mcg/kg with a 5-minute lockout)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Physician-controlled analgesia with continuous infusions (0.75 mcg/kg/min) and intermittent boluses (5 mcg/kg) of alfentanil
Number of subjects: 62
Study: 1836062

Group type: EXPERIMENTAL
Intervention: Fish diet (0.15 g EPA/d, 0.41 g DHA/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fish + Oil diet (0.99 g EPA/d, 0.99 g DHA/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fish oil alone (5 g/d for 6 weeks, 0.84 g EPA/d, 0.48 g DHA/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Essentially fish-free control diet
Number of subjects: 21
Study: 6992909

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Both groups (naftidrofuryl and control)
Number of subjects: 128
Study: 31603245

Group type: EXPERIMENTAL
Intervention: 3-month strict oral hygiene phase
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no instructions or motivation on oral hygiene)
Number of subjects: 44
Study: 31562715

Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemodiafiltration (CVVHDF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous arterio-venous hemodiafiltration (CAVHDF)
Number of subjects: 30
Study: 28286605

Group type: EXPERIMENTAL
Intervention: Synbiotic (Lactobacillus casei + inulin)
Number of subjects: 32
Study: 25895747

Group type: EXPERIMENTAL
Intervention: Pedometer-driven walking programme with educational material (n = 29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group receiving educational material only (n = 29)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pedometer-driven walking programme (n = 29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (n = 29)
Number of subjects: 58
Study: 24045865

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) 180 min/week (n = 16)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE) 180 min/week (n = 16)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-exercising control (C) (n = 12)
Number of subjects: 44
Study: 22045826

Group type: EXPERIMENTAL
Intervention: Negative colposcopy or biopsy without CIN
Number of subjects: 551

Group type: COMPARATOR
Intervention: Routine screening at intervals of three or five years
Number of subjects: 551
Study: 19900257

Group type: EXPERIMENTAL
Intervention: EQ-5D health states valuation using TTO
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: EQ-5D health states valuation using VAS
Number of subjects: 611

Group type: COMPARATOR
Intervention: Comparison of Argentine TTO values with US values
Number of subjects: 611
Study: 17986292

Group type: EXPERIMENTAL
Intervention: Pseudoexfoliation (PEX) syndrome
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Open-angle glaucoma (OAG)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Mortality
Number of subjects: 339
Study: 15471059

Group type: EXPERIMENTAL
Intervention: Telephone calls (experimental group, n = 41)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Attention-only control (n = 42)
Number of subjects: 83
Study: 11488382

Group type: EXPERIMENTAL
Intervention: Counter model for word identification
Number of subjects: 0
Study: 9703167

Group type: EXPERIMENTAL
Intervention: Additional service by a specialist team
Number of subjects: 314

Group type: COMPARATOR
Intervention: Existing standard services
Number of subjects: 314
Study: 7994666

Group type: EXPERIMENTAL
Intervention: Verapamil SR 240 mg (oral administration)
Number of subjects: 3
Study: 2563744

Group type: EXPERIMENTAL
Intervention: A single oral dose of 8.8 mg azelastine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 197446

Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (15 to 60 mg, subcutaneously administered)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31910028

Group type: COMPARATOR
Intervention: Lipid trial (acute feeding study)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-fat diet (+25% energy excess) (chronic study)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Acute and short-term dietary fat overload
Number of subjects: 17
Study: 31565898

Group type: EXPERIMENTAL
Intervention: NA-XY (nalbuphine-xylazine combination: xylazine 1.1mL/100 kg IV and nalbuphine 1 mg/kg IV)
Number of subjects: 5

Group type: COMPARATOR
Intervention: XY (xylazine 1.1mL/100 kg IV)
Number of subjects: 5
Study: 29164254

Group type: EXPERIMENTAL
Intervention: Oral insulin (7.5 mg/d)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Overall cohort (560 participants)
Number of subjects: 560
Study: 24711046

Group type: EXPERIMENTAL
Intervention: Routine Family Therapy (RFT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 45
Study: 23644823

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) - up to 1500 mg iron
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21481942

Group type: EXPERIMENTAL
Intervention: Short cue
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Vertical cue
Number of subjects: 123

Group type: COMPARATOR
Intervention: Long cue
Number of subjects: 123

Group type: COMPARATOR
Intervention: Oblique cue
Number of subjects: 123
Study: 18080768

Group type: EXPERIMENTAL
Intervention: Active ulcerative colitis (UC) patients
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Active Crohn's disease (CD) patients
Number of subjects: 89

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Correlation with disease activity markers
Number of subjects: 89
Study: 17138086

Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 30
Study: 12826316

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP) - gemcitabine 1200 mg/m² on days 1 and 8 plus cisplatin 80 mg/m² on day 2.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC) - gemcitabine 1200 mg/m² on days 1 and 8 plus carboplatin AUC=5 on day 2.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC)
Number of subjects: 120
Study: 10671908

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 13

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 13
Study: 9124195

Group type: EXPERIMENTAL
Intervention: Gallium nitrate 200 mg/m2/day and hydroxyurea 500 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gallium nitrate 250 mg/m2/day and hydroxyurea 1,000 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gallium nitrate 300 mg/m2/day and hydroxyurea 1,000 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gallium nitrate 350 mg/m2/day and hydroxyurea 1,000 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of gallium nitrate and hydroxyurea
Number of subjects: 14
Study: 8227897

Group type: EXPERIMENTAL
Intervention: L-deprenyl
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 2940475

Group type: EXPERIMENTAL
Intervention: Transdihydrolisuride (1 mg daily)
Number of subjects: 10
Study: 31827359

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-fat (LCHF) diet
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-carbohydrate, low-fat (HCLF) diet
Number of subjects: 7
Study: 29424885

Group type: EXPERIMENTAL
Intervention: Balloon catheter dilation (BCD)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional endoscopic sinus surgery (ESS)
Number of subjects: 102
Study: 26914542

Group type: EXPERIMENTAL
Intervention: CNI-withdrawal (n = 23)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CNI-minimization (n = 17)
Number of subjects: 40
Study: 24366547

Group type: EXPERIMENTAL
Intervention: Microbial immune enteral nutrition
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 22241678

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study: 20447260

Group type: EXPERIMENTAL
Intervention: Autogenous bone graft + GTR
Number of subjects: 40

Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 40
Study: 17592099

Group type: EXPERIMENTAL
Intervention: Pravastatin, vitamin E, and homocysteine lowering therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93